CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult
Enhertu wins EU approval for HER2-positive early breast cancer treatment
Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418
Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers